Table 1.
Overall | Study 1 | Study 2 | |
---|---|---|---|
Number of subjects | 1085 | 682 | 403 |
Females (%) | 61 | 65 | 55** |
Asthma age-of-onset < 6 (%) | 31 | 27 | 38*** |
Family history of allergic disease (%) | 81 | 76 | 92*** |
Eczema (%) | 34 | 32 | 38* |
Hayfever (%) | 64 | 55 | 77*** |
Atopy (%), N = 402 | 81 | 81 | 81 |
FEV1 < 80% predicted (%)a, N = 468 | 19 | 19 | 19 |
Mean log total serum IgE (range), N = 444 | 4.7 (0.7–8.4) | 4.4 (0.7–7.6) | 4.9 (1.6–8.4)** |
FEV1, Forced expiratory volume after 1 second; IgE, Immunoglobulin E.
Significant difference in frequency or mean when compared to Study 1:
P < 0.05;
P < 0.005;
P < 0.0005.
Predicted FEV1 was calculated based on each subject's age and sex.